Hypersensitivity to aspirin: Common eicosanoid alterations in urticaria and asthma

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 4, 2004, Pages 771-775

  Mastalerz, Lucyna ^a   Setkowicz, Malgorzta ^a   Sanak, Marek ^a   Szczeklik, Andrew ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Aspirin; Asthma; Eicosanoids; NSAIDs; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; ICOSANOID; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE E4; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN D2; PROSTAGLANDIN F2;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; BREATHING DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; GENE FREQUENCY; GENOTYPE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN BLOOD LEVEL; PROVOCATION TEST; RHINORRHEA; SINGLE BLIND PROCEDURE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; URTICARIA;

EID: 1942500163     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.12.323     Document Type: Article

References (43)

1. Settipanne GA. Landmark commentary: history of aspirin intolerance. Allergy Proc 1990;11:251-3.
2. Samter M, Beers RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-83.
3. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21.
4. Szczeklik A, Nizankowska E, Duplaga M, on behalf of the AIANE Investigators. Natural history of aspirin-induced asthma. Eur Respir J 2000;16:432-6.
5. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:472-8.
6. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67-9.
7. Folco G, Samuelsson B, Murphy RC. Novel inhibitors of leukotrienes. Basel/Boston: Birkhauser Verlag; 1999.
8. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31.
9. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal antiinflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977;60:276-84.
10. Setkowicz M, Zembowicz A, Mastalerz L, Radziszewski W, Szczeklik A. Non-steroidial anti-inflammatory drugs (NSAID) sensitivity in chronic idiophatic urticaria CIU: selective involvement of cyclooxygenase 1 (COX-1) and overproduction of cysteinyl-leukotrienes. J Allergy Clin Immunol 2003;111:S272.
11. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 11 inhibitors and increased leukotriene synthesis in chronic idiophatic urticaria with sensitivity to non-steroidial anti-inflammatory drugs. Arch Dermatol 2003;139:1577-82.
12. Berges-Gimeno MP, Camacho-Garrido E, Garcia Rodriguez RM, Martin-Garcia C, Alfaya-Arias T, Prieto P, et al. Rofecoxib, a slelective high affinity COX-2 inhibitor has proved to be safe in urticaria/ angioedema associated with NSAID intolerance. Allergy 2001;56:49.
13. Pacor ML, Di Lorenzo G, Biasi D, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or nonsteroidial anti-inflammatory drugs. Clin Exp Allergy 2002;109:S140.
14. Nettis E, Di PR, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidial anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002:88331-4.
15. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonesca F. How safe are COX-2 inhibitors in NSAID-sensitive subjects with cutaneous reactions. ACI Int 2003;15:110-3.
16. Frederiksson T, Pettersson U. Severe psoriasis: oral therapy with new retinoid. Dermatologica 1978;157:238-44.
17. 4 in humans. Clin Exp Allergy 1995;25:467-79.
18. 2 in human urine and plasma by gas chromatography - mass spectrometry. J Chromatogr 1994; 655:173-8.
19. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600.
20. Nasser SM, Lee TH. Leukotrienes and aspirin-sensitive asthma. In: Szczeklik A, Gryglewski R, Vane J, editors. Eicosanoids, aspirin and asthma New York: Marcel Dekker Inc; 1998. p. 317-33.
21. 2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003;111:743-9.
22. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981;104:369-81.
23. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti inflammatory drugs. In: Middleton E, edtior. Allergy. Principles and practice. St Louis: Mosby; 1998. p. 1225-34.
24. Di Lorenzo G, Pacor ML, Vignola AM, Profita M, Esposito-Pellitteri M, Biasi D, et al. Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. Allergy 2002;57:1180-6.
25. 2 on this release from peripherial blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001;31:1615-22.
26. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001;31:1607-14.
27. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110:484-8.
28. Marone G, Lichtenstein LM, Galli SJ. Mast cells and basophils. San Diego: Academic Press; 2000.
29. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-604.
30. Fiebiger E, Maurer D, Holub H, Reininger B, Hartman G, Wolsetschläger M, et al. Serum IgG autoantibodies directed against the α chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?. J Clin Invest 1995;96:2606-12.
31. Ferrer M, Kinet J-P, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcεRI α (α-subunit) in chronic urticaria. J Allergy Clin Immunol 1998;101:672-6.
32. Greaves MW. Pathophysiology of chronic urticaria. Int Arch Allergy Immunol 2002;127:3-9.
33. Kaplan A. Chronic urticaria and angioedema. N Engl J Med 2002;346: 175-9.
34. Asero R, Tedeshi A, Lorini M. Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol 2002;88:468-72.
35. Szczeklik A, Niżankowska E, Serafin A, Dyczek A, Duplaga M, Musial J. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995;152:1753-6.
36. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Investig Dermatol 1983;80:115-9.
37. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Med Biol 2000;23:290-6.
38. 4 synthase does not correlate with the aspirin-intolerant phenotype in the United States. J Allergy Clin Immunol 2000;106:72-6.
39. Sayers I, Barton S, Rorke S, Beghé, Hayward B, Van Eerdewegh P, et al. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Thorax 2003;58: 417-27.
40. 4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000;55:528-31.
41. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002;12:565-70.
42. 2. Lancet 1995;345:436-8.
43. 2 and aspirin-induced asthma. Lancet 1995; 345:1056.